Using Dexamethasone to Prevent Recurrence of Anaphylaxis in Children
Use of Dexamethasone in Prevention of the Second Phase or a Biphasic Reaction of Anaphylaxis
This study is testing if giving dexamethasone to children with mild to moderate anaphylaxis can help prevent a second allergic reaction that might happen later.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 210 (estimated) |
| Ages | 3 Months to 14 Years |
| Sex | All |
| Sponsor | Hamad Medical Corporation Industry-sponsored |
| Locations | 1 site (Doha) |
| Trial ID | NCT03523221 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of oral dexamethasone in preventing the second phase or biphasic reaction of anaphylaxis in children aged 3 months to 14 years who present with mild to moderate anaphylaxis at the Pediatric Emergency Department in Doha, Qatar. Participants will be randomly assigned to receive either dexamethasone or a placebo. The study seeks to determine if dexamethasone can reduce the incidence of late-phase reactions that can occur 8-12 hours after the initial anaphylactic episode. The findings could provide insights into improving treatment protocols for pediatric anaphylaxis.
Who should consider this trial
Good fit: Ideal candidates for this study are children aged 3 months to 14 years who present with mild to moderate anaphylaxis.
Not a fit: Patients with severe anaphylaxis or those with a history of immunological diseases or on steroid therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for children experiencing anaphylaxis, potentially reducing the risk of severe late-phase reactions.
How similar studies have performed: While the use of corticosteroids in anaphylaxis management is common, the specific approach of using dexamethasone to prevent biphasic reactions is less established, making this study a novel investigation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients 3 monthes-14years presenting to the Pediatric Emergency Department (AlSadd) with mild to moderate anaphylaxis Exclusion Criteria: Patients with severe anaphylaxis. Patient with history of immunological diseases. Patients on steroids therapy Patient with moderate-severe asthma on medication Patients with severe asthma
Where this trial is running
Doha
- Hamad Medical Corporation — Doha, Qatar (Recruiting)
Study contacts
- Principal investigator: Khalid Al ansari, FRCP — Hamad Medical Corporation
- Study coordinator: Rafah Sayyed, Md
- Email: ralsayyed@hamad.qa
- Phone: +974-55747045
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.